NCT01245985终止2 期
Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Local-Regional Control (LRC)
研究概览
简要总结
TPF-C-HIT investigates the combination of induction chemotherapy with TPF followed by radioimmunotherapy with cetuximab and IMRT plus carbon ion boost with regard to efficacy and toxicity of the combination regimen.
详细描述
TPF-C-HIT is a prospective, monocentric phase II trial efficacy, as measured by control and survival rates, as well as toxicity (acute and late effects) of the combined treatment with TPF-induction followed by radioimmunotherapy with the EGFR-antibody cetuximab and carbon ion boost in locally advanced squamous cell carcinoma of the head and neck (SCCHN). As long-term local control remains a therapeutic challenge in advanced head and neck cancer, locoregional control was chosen as the primary endpoint. Secondary endpoints are survival rates (disease-free survival, PFS, OS), acute and late radiation effects as well as adverse events. For development of prognostic markers, proteomic and genomic analyses are also included in the secondary endpoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent,
- •Age of 18 to 70 years,
- •Life expectancy of at least 6 month,
- •Ability of subject to understand character and individual consequences of clinical trial,
- •Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx and larynx (T2-4, any N, M0),
- •Oral cavity or oro- , hypopharynx or laynx as the primary tumor site,
- •At least one uni-measurable lesion according to the RECIST criteria, Karnofsky Performances Status > 70%,
- •Adequate bone marrow function: neutrophils > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin > 10.0 g/dL,
- •Adequate liver function: Bilirubin < 1.5 mg/dL, SGOT, SGPT < 3 x ULN, GGT < 5 x ULN,
- •Adequate renal function: GFR> 70 ml/min,
- •Negative serum/urine Beta-HCG test in women of childbearing potential,
- •Women of childbearing potential: willingness to use effective contraceptive method, defined as the concomitant use of either an intrauterine pessary (IUP) or contraceptive pill and in both cases, condoms for the treatment duration and 2 months thereafter. Women of non-childbearing potiential are those who are post-menopausal for at least 1 year or sterilized,
- •Men of procreative potential: willingness for effective prevention of procreation, defined as a use of condoms and a use of either an intrauterine pessary (IUP) or a contraceptive pill by his partner for the treatment duration and 2 months thereafter,
- •Subject's consent to collect blood and/or tumor tissue samples for proteomics and genomics. If a patient does not consent, no samples for proteomics and genomics will be taken. Nonetheles, he/she may be enroled in the study
排除标准
- •Previous systemic chemotherapy, radiotherapy or surgery for carcinoma of the head, neck and larynx,
- •Nasopharyngeal Carcinoma,
- •Prior exposure to EGFR pathway targeting therapy,
- •Evidence of distant metastases.
- •Other serious illness or medical conditions:
- •Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4,
- •Significant neurologic or psychiatric disorders including dementia or seizures,
- •Active disseminated intravascular coagulation,
- •Other serious underlying medical conditions which in the opinion of investigator could impair the ability of the patient to participate in the study,
- •Symptomatic peripheral neuropathy Common Toxicity Criteria (CTC) grade 2 or higher,
- •ototoxicity CTC grade 2 or higher, except if due to trauma or mechanical impairment due to tumor mass,
- •Participation in other interventional trial within the last 30 days§§,
- •Surgery within the last 30 days,
- •Known allergic/hypersensitivity reaction to any drugs scheduled for the study treatment,
- •Women: pregnant or breast-feeding,
- •Known drug abuse,
- •Other previous malignancy within 5 years, with exception of a history of a previous, adequately treated, basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix,
- •Legal incapacity or limited legal capacity,
- •Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
结局指标
主要结局
Local-Regional Control (LRC)
时间窗: 12 months
The primary endpoint of the study is the Local-Regional Control (LRC) at 1 year
次要结局
- disease-free survival (DFS)(12 months)
- progression-free survival (PFS)(12 months)
- overall survival (OS)(12 months)
- acute radiation effects(6 weeks post completion of radiotherapy)
- late radiation effects(12 months)
- adverse events(12 months)
- proteomic and genomic analyses(6 measuring points: days 50, 64, 73, 106 of treatment; 6 weeks post completion of radioimmunotherapy; 3 months post completion of radioimmunotherapy)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal CarcinomaChildrenNasopharyngeal CarcinomaNCT03020329Sun Yat-sen University37
进行中（未招募）
3 期
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT03306121Sun Yat-sen University322
进行中（未招募）
不适用
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）ESCCNCT06478355Hebei Medical University Fourth Hospital800
尚未招募
3 期
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04414566West China Hospital562
已完成
2 期
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasPrimary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's LymphomaNCT00521560Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH28